224 related articles for article (PubMed ID: 22695089)
1. Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer.
Kim YJ; Hong YB; Cho CH; Seong YS; Bae I
Pancreas; 2012 Jul; 41(5):804-5. PubMed ID: 22695089
[No Abstract] [Full Text] [Related]
2. Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer.
Hong YB; Kim JS; Yi YW; Seong YS; Bae I
Pancreas; 2012 Apr; 41(3):496-8. PubMed ID: 22415672
[No Abstract] [Full Text] [Related]
3. Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.
Saini P; Li Y; Dobbelstein M
Oncotarget; 2015 May; 6(15):13072-87. PubMed ID: 25965828
[TBL] [Abstract][Full Text] [Related]
4. In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better.
Mura S; Buchy E; Askin G; Cayre F; Mougin J; Gouazou S; Sobot D; Valetti S; Stella B; Desmaele D; Couvreur P
Biochimie; 2016 Nov; 130():4-13. PubMed ID: 27519301
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.
Venkatesha VA; Parsels LA; Parsels JD; Zhao L; Zabludoff SD; Simeone DM; Maybaum J; Lawrence TS; Morgan MA
Neoplasia; 2012 Jun; 14(6):519-25. PubMed ID: 22787433
[TBL] [Abstract][Full Text] [Related]
6. [Gemcitabine chemotherapy for patients with advanced or relapsed pancreatic cancer].
Ohkawa S
Nihon Rinsho; 2006 Jan; 64 Suppl 1():198-202. PubMed ID: 16457249
[No Abstract] [Full Text] [Related]
7. RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
Hong SK; Yang SY; Yin SH; Yang KX
Pancreas; 2014 Jan; 43(1):15-21. PubMed ID: 24326363
[TBL] [Abstract][Full Text] [Related]
8. The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.
Köpper F; Binkowski AM; Bierwirth C; Dobbelstein M
Cell Cycle; 2014; 13(6):884-9. PubMed ID: 24556918
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of randomized trials: evaluation of benefit of gemcitabine-based molecular targeted therapy for inoperable pancreatic cancer.
Cao Y; Wu L; Tan A; Liu L; Liao C; Gao F
Pancreas; 2010 Mar; 39(2):253-5. PubMed ID: 20182311
[No Abstract] [Full Text] [Related]
10. Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer.
Liu QH; Zhang J; Zhao CY; Yu DH; Bu HJ; Chen Y; Ni CY; Zhu MH
Cancer Lett; 2012 Jan; 314(1):119-25. PubMed ID: 21983131
[TBL] [Abstract][Full Text] [Related]
11. Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.
Liu DL; Bu H; Li H; Chen H; Guo HC; Wang ZH; Tong HF; Ni ZL; Liu HB; Lin SZ
Int J Oncol; 2012 Apr; 40(4):1049-57. PubMed ID: 22159556
[TBL] [Abstract][Full Text] [Related]
12. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
Hashim YM; Vangveravong S; Sankpal NV; Binder PS; Liu J; Goedegebuure SP; Mach RH; Spitzer D; Hawkins WG
J Exp Clin Cancer Res; 2017 Jan; 36(1):14. PubMed ID: 28095907
[TBL] [Abstract][Full Text] [Related]
13. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.
Thoennissen NH; Iwanski GB; Doan NB; Okamoto R; Lin P; Abbassi S; Song JH; Yin D; Toh M; Xie WD; Said JW; Koeffler HP
Cancer Res; 2009 Jul; 69(14):5876-84. PubMed ID: 19605406
[TBL] [Abstract][Full Text] [Related]
14. Quercetin induces apoptosis and enhances gemcitabine therapeutic efficacy against gemcitabine-resistant cancer cells.
Liu ZJ; Xu W; Han J; Liu QY; Gao LF; Wang XH; Li XL
Anticancer Drugs; 2020 Aug; 31(7):684-692. PubMed ID: 32282368
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
Fryer RA; Barlett B; Galustian C; Dalgleish AG
Anticancer Res; 2011 Nov; 31(11):3747-56. PubMed ID: 22110196
[TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.
Uehara M; Domoto T; Takenaka S; Bolidong D; Takeuchi O; Miyashita T; Minamoto T
Cancer Sci; 2020 Dec; 111(12):4405-4416. PubMed ID: 32986894
[TBL] [Abstract][Full Text] [Related]
17. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway.
Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L
Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modulation and attacking the hedgehog pathway: potentially synergistic therapeutic targets for pancreatic cancer.
Freeman JW; Wang Y; Giles FJ
Cancer Biol Ther; 2009 Jul; 8(14):1340-2. PubMed ID: 19440037
[No Abstract] [Full Text] [Related]
19. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
[TBL] [Abstract][Full Text] [Related]
20. Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells.
Kim R; Yamauchi T; Husain K; Sebti S; Malafa M
Anticancer Res; 2015 Sep; 35(9):4599-604. PubMed ID: 26254348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
